Actinium Successfully Completes First Module of Collaborative Research Program with Astellas; Second Module Initiated Jan 17, 2019
Actinium Pharmaceuticals Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation Conjugate Therapies Jan 16, 2019
Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting Dec 4, 2018
Actinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate Dec 3, 2018
Actinium Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference Nov 19, 2018
Actinium Pharmaceuticals to Present at BIO-Europe® 24th Annual International Partnering Conference Nov 5, 2018
Actinium Pharmaceuticals ASH Annual Meeting Presence to Include Oral Presentation of Feasibility and Safety Results of Iomab-B Pivotal Phase 3 SIERRA Trial and also New Actimab-A Phase 2 Trial Data Nov 1, 2018
Actinium Pharmaceuticals CD33 Program to Focus on Actimab-MDS Pivotal Trial Enabling Study for Targeted Conditioning and Novel Combination Trials with Actimab-A and Venetoclax Oct 30, 2018
Actinium Pharmaceuticals to Hold Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update Oct 26, 2018
